Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Docetaxel-Gemcitabine in Metastatic Breast Cancer
NCT00191243Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2002
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to Treatment Failure. Started Mar 2002; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00191243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191243.